504 views
October 1, 2024

Chapters

DESTINY-Breast12 Outcomes & Trastuzumab Deruxtecan Efficacy

00:00

Guideline Changes & T-DXd as Preferred Option

04:59

New ADCs: Patritumab & Comparable Data

06:01

Emerging ADCs & ESG401 Intracranial Response

08:33

Novel Bispecific Drugs & CAPItello-290 Findings

10:25

Tailoring ADCs & DESTINY-Breast06 Biomarkers

12:52

Predictive Biomarkers & ICARUS Trial Insights

16:54

Optimal Chemo Partners for Immune Checkpoint Inhibitors

18:14

Comments 0
Login to view comments. Click here to Login